STAT Partners with Applied XL to Launch New AI-Powered Clinical Trial Monitoring Platform

0

STAT Trials Pulse provides life science professionals with early signals on clinical development, accelerating decision-making on partnerships, regulatory strategy, investments, and more.

BOSTON, January 21, 2022 /PRNewswire/ — Since 2015, our team of STAT has worked tirelessly to deliver trusted and authoritative journalism on health, medicine and life sciences to millions of readers around the world. We are excited to unveil a new product that has been in development for over a year and which we believe will transform the way readers like you track and analyze clinical trial data: STAT test pulse.

STAT

Developed by an artificial intelligence company Applique XL, in collaboration with STAT’s National Biotechnology Team, STAT Trials Pulse uses machine learning and editorial algorithms to help life science and healthcare professionals identify, in real-time, critical updates. most important in the field of clinical trials.

“Our team has created a product that merges machine learning and computer journalism. There is a growing demand for current and transparent information in the scientific and research community. STAT Trials Pulse meets these needs, giving users an unbeatable competitive advantage,” said Francesco Marconi, co-founder and CEO of Applied XL.

Users accessing the platform can create personalized and dynamic feeds to monitor the specific conditions, responses and organizations that matter most to them. They can also use a proprietary discovery tool to highlight notable trends in clinical trials, identify emerging research activities, and detect disruptions in company pipelines. And, most importantly, they receive these updates in real time, through contextualized alerts that announce the unexpected termination of studies or changes in completion dates, registration, etc. You can see a full list of features at statnews.com/trials-pulse.

“Our mission at STAT has always been to provide readers with leading coverage of health, science and medicine. Now, STAT extends beyond reporting. With STAT Trials Pulse, our organization has made a big step forward in providing industry professionals with the information and knowledge they need to succeed. Today’s announcement is a game-changer in how we use technology to acquire insights,” said Rick Berke, co-founder and editor-in-chief of STAT.

The annual cost of the platform is $1,500 per year. STAT Trials Pulse is available for a free four-week trial to all new users who sign up. start to https://trials.appliedxl.com.

ABOUT STAT:
Founded in 2015, STAT is a national digital media brand focused on delivering fast, in-depth, and rigorous journalism about the life sciences industries to over six million monthly visitors and an additional 20 million readers. on the Apple News app. STAT takes you into university labs, biotech boardrooms, and the political backstage, casting a critical eye over scientific discoveries, scrutinizing corporate strategies, and chronicling tumultuous battles for talent, money, and market share. . With an award-winning newsroom, STAT provides indispensable information and exclusive stories about the technologies, personalities, power brokers and political forces driving massive change in the life sciences industry – and a revolution in human health.

ABOUT APPLIED XL:
Founded in 2020, Applied XL develops real-time information systems to track the health of people, places and the planet to accelerate the path to sustainable growth. Applied XL combines pioneering computer journalism techniques and expert networks to power intuitive intelligence products for professionals in specialized industries. The company is made up of computer journalists and machine learning engineers.

Quote

Quote

View original content for multimedia download: https://www.prnewswire.com/news-releases/stat-partners-with-applied-xl-to-launch-a-new-clinical-trials-monitoring-platform-powered -by -artificial-intelligence-301465973.html

SOURCE STATISTICS

Share.

About Author

Comments are closed.